B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI
B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to its most recent disclosure with the...
MarketBeat·14h ago
More News
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Denali Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat·2d ago
Leerink Partners Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $35.00
Leerink Partners reduced their price target on Denali Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday...
MarketBeat·4d ago
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
Zacks·9d ago
Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co.
Baillie Gifford & Co. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the...
MarketBeat·14d ago
Q3 EPS Estimate for Denali Therapeutics Increased by Analyst
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - HC Wainwright boosted their Q3 2026 EPS estimates for shares of Denali Therapeutics in a note issued to investors on Tuesday, April 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.73) per share for the q...
MarketBeat·17d ago
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
Zacks·19d ago
Denali Therapeutics (NASDAQ:DNLI) Given New $34.00 Price Target at Robert W. Baird
Robert W. Baird upped their price target on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday...
MarketBeat·19d ago
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.read more...
Benzinga·20d ago
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9% - Here's What Happened
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9% - Should You Sell...